JMS Co

JMS Co EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of JMS Co (7702.T) as of Nov 2, 2026 is 81.10. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was 22.43 — a change of 261.50% (higher).

EV/EBITDA

81.10

YoY

261.50%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of JMS Co is 2026 81.10 . EV/EBITDA (Enterprise Value to EBITDA) of JMS Co was 2025 22.43 . It decreases by 261.50% higher compared to the previous year.

The JMS Co EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2019
12.49 JPY
Jan 1, 2020
8.16 JPY
Jan 1, 2021
8.77 JPY
Jan 1, 2022
16.63 JPY
Jan 1, 2023
21.00 JPY
Jan 1, 2024
35.80 JPY
Jan 1, 2025
22.43 JPY
Jan 1, 2026
81.10 JPY
The JMS Co EV/EBITDA history
YEAREV/EBITDAYoY
81.10+261.50%
22.43-37.34%
35.80+70.48%
21.00+26.32%
16.63+89.67%
8.77+7.42%
8.16-34.67%
12.49-30.17%
17.88+19.33%
14.99+28.57%
11.66-50.12%
23.37+75.26%
13.33—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

JMS Co Stock analysis

What does JMS Co do? JMS Co., Ltd. generates revenue through the manufacture, sale, export, and import of medical devices and pharmaceuticals across its five geographical segments: Japan, Singapore, China, Philippines, and Germany. The company offers a range of products including infusion and nutrition products, dialysis products, surgery products, blood and cell products, and other related items. Key products such as infusion & transfusion sets, syringe pumps, surgical gowns, dialysis kits, peritoneal dialysate, microcatheters, and blood bags are sold to healthcare providers and institutions within these regions. The firm also provides maintenance services and other related services as part of its product portfolio. The company's primary customers are healthcare providers and institutions in Japan, Singapore, China, Philippines, and Germany, where it operates through its five geographical segments. These customers purchase medical equipment and drugs, including specific items like infusion & transfusion sets, dialysis kits, and surgical gowns. The firm's product lines are tailored to meet the needs of hospitals, clinics, and other medical facilities across its operational regions. JMS Co., Ltd. focuses on manufacturing and selling medical equipment and drugs, with a strong emphasis on products such as infusion & transfusion sets, syringe pumps, surgical gowns, and dialysis kits. The company's revenue streams are driven by the sale of these products and the provision of maintenance services. Its geographical segments ensure a diversified market presence, allowing it to serve various healthcare sectors in different countries. JMS Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about JMS Co stock

EV/EBITDA (Enterprise Value to EBITDA) of JMS Co is 81.10 in 2026.

EV/EBITDA (Enterprise Value to EBITDA) of JMS Co changed from 22.43 to 81.10, representing a 261.50% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) JMS Co since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s JMS Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — JMS Co

All Key Metrics — JMS Co